LONDON, Dec. 4 /PRNewswire/ -- Spirogen Ltd announced the appointments of J. Barrie Ward as a Chairman of the Board of Directors and Christopher J. Pugh as Chief Business Officer.
Dr. Ward brings a tremendous wealth of leadership skills and experiences to Spirogen Ltd. He is currently Chairman of the Board of Directors of AVANT Immunotherapeutics Inc. and Onyvax Ltd. He has served as Chief Executive Officer of KuDOS Pharmaceuticals Ltd and Chief Executive Officer and Chairman of the Board of Directors of Virus Research Institute, Inc. Earlier in his career, Dr. Ward worked in research for Glaxo Ltd., where he became Director of the Microbiology Division of Glaxo Research and Development Ltd.
Mr. Pugh brings a wealth of commercial and business development skills and experiences. Previously he served as Vice President, Business Development at Genitrix LLC which develops innovative immunotherapeutic products. While at Genitrix he developed a number of key agreements with top tier Multinational Pharmaceutical companies. Prior to that he served as Vice President of Business Development for Bioject Inc. While at Bioject he negotiated a number of external agreements, including one that offered the largest potential payout in that company's 18-year history. Prior to that, he was Director of Business Development at Guilford Pharmaceuticals Inc., which developed and marketed small molecule therapeutics for cancer and other serious conditions. Mr. Pugh began his career working for Procter & Gamble Pharmaceuticals.
Dr. Chris Martin, CEO of Spirogen, said, "We are delighted that both Barrie and Chris have chosen to join us. As we move to our next phase, expanding our development and commercial efforts, their experiences will help us considerably."
About Spirogen (http://www.spirogen.com)
Spirogen is a clinical stage biotechnology company specializing in the development of DNA targeted therapies for major diseases. The company was founded in 2000, has 28 employees and is venture capital funded.
Spirogen's lead oncology drug candidate, SG 2000 (SJG-136), is currently being evaluated in four Phase 1 Studies in Europe and USA.
In addition, the company has a diverse portfolio of five further products which are in preclinical development and are patented extensively.
Spirogen LtdCONTACT: Christopher J. Pugh of Spirogen Ltd, +1-215-962-2028
Web site: http://www.spirogen.com/
